Prentiss Smith & Co. Inc. maintained its position in Bristol-Myers Squibb Company (NYSE:BMY) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,333 shares of the biopharmaceutical company’s stock at the end of the second quarter. Prentiss Smith & Co. Inc.’s holdings in Bristol-Myers Squibb were worth $130,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in BMY. Patten & Patten Inc. TN boosted its stake in shares of Bristol-Myers Squibb by 2.1% in the 1st quarter. Patten & Patten Inc. TN now owns 132,428 shares of the biopharmaceutical company’s stock valued at $7,201,000 after purchasing an additional 2,717 shares in the last quarter. Nisa Investment Advisors LLC boosted its stake in shares of Bristol-Myers Squibb by 1.8% in the 1st quarter. Nisa Investment Advisors LLC now owns 610,253 shares of the biopharmaceutical company’s stock valued at $33,186,000 after purchasing an additional 10,541 shares in the last quarter. Quantitative Systematic Strategies LLC boosted its stake in shares of Bristol-Myers Squibb by 447.5% in the 1st quarter. Quantitative Systematic Strategies LLC now owns 32,128 shares of the biopharmaceutical company’s stock valued at $1,747,000 after purchasing an additional 26,260 shares in the last quarter. Hartford Financial Management Inc. boosted its stake in shares of Bristol-Myers Squibb by 1.8% in the 1st quarter. Hartford Financial Management Inc. now owns 69,247 shares of the biopharmaceutical company’s stock valued at $3,765,000 after purchasing an additional 1,223 shares in the last quarter. Finally, Ledyard National Bank boosted its stake in shares of Bristol-Myers Squibb by 25.5% in the 1st quarter. Ledyard National Bank now owns 27,248 shares of the biopharmaceutical company’s stock valued at $1,482,000 after purchasing an additional 5,533 shares in the last quarter. 68.88% of the stock is owned by institutional investors and hedge funds.

ILLEGAL ACTIVITY WARNING: This piece was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this piece on another publication, it was illegally copied and republished in violation of international copyright law. The legal version of this piece can be viewed at https://www.thecerbatgem.com/2017/09/19/prentiss-smith-co-inc-maintains-stake-in-bristol-myers-squibb-company-bmy.html.

A number of equities research analysts have recently issued reports on the stock. Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and issued a $65.00 price objective (up previously from $62.00) on shares of Bristol-Myers Squibb in a research note on Thursday, September 7th. Vetr cut shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating and set a $64.20 price objective for the company. in a research note on Thursday, September 7th. Credit Suisse Group reaffirmed a “hold” rating on shares of Bristol-Myers Squibb in a research note on Friday, September 8th. Jefferies Group LLC upped their price objective on shares of Bristol-Myers Squibb from $66.00 to $72.00 and gave the company a “buy” rating in a research note on Monday, September 11th. Finally, Hilliard Lyons cut shares of Bristol-Myers Squibb from a “long-term buy” rating to a “neutral” rating and set a $65.00 price objective for the company. in a research note on Tuesday, September 12th. One equities research analyst has rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the stock. The stock has an average rating of “Hold” and an average price target of $62.66.

In related news, Director Theodore R. Samuels II bought 6,000 shares of the stock in a transaction dated Wednesday, August 2nd. The stock was purchased at an average cost of $55.94 per share, with a total value of $335,640.00. Following the completion of the purchase, the director now owns 18,000 shares of the company’s stock, valued at $1,006,920. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Joseph C. Caldarella sold 9,340 shares of the business’s stock in a transaction on Wednesday, September 6th. The shares were sold at an average price of $60.00, for a total transaction of $560,400.00. Following the sale, the senior vice president now directly owns 46,297 shares of the company’s stock, valued at $2,777,820. The disclosure for this sale can be found here. 0.23% of the stock is currently owned by insiders.

Shares of Bristol-Myers Squibb Company (NYSE BMY) traded up 0.57% on Tuesday, reaching $63.06. 1,982,154 shares of the company’s stock traded hands. The firm has a market cap of $103.41 billion, a P/E ratio of 23.03 and a beta of 1.18. Bristol-Myers Squibb Company has a 12-month low of $46.01 and a 12-month high of $63.47. The stock has a 50-day moving average of $58.77 and a 200 day moving average of $55.98.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.73 by $0.01. The firm had revenue of $5.14 billion during the quarter, compared to analyst estimates of $5.09 billion. Bristol-Myers Squibb had a net margin of 22.66% and a return on equity of 32.33%. The business’s revenue was up 5.6% on a year-over-year basis. During the same period in the previous year, the firm earned $0.69 earnings per share. On average, equities research analysts expect that Bristol-Myers Squibb Company will post $2.98 earnings per share for the current year.

The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 1st. Stockholders of record on Friday, October 6th will be paid a dividend of $0.39 per share. This represents a $1.56 dividend on an annualized basis and a dividend yield of 2.49%. The ex-dividend date is Thursday, October 5th. Bristol-Myers Squibb’s dividend payout ratio is currently 56.73%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Company (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Stock Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related stocks with our FREE daily email newsletter.